IRCT2015102524679N2已完成2 期
A comparative study on efficacy of Deferasirox (Exjade) versus Osveral in treatment of iron overload in patients with beta thalassemia major
Investigator0 个研究点目标入组 69 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 50 years（—）
- 性别
- All
入选标准
- •equal or more than 2 years old; normal creatinine level; no proteinuria; negative for hepatitis B and C or HIV; hepatic transaminase less than 5 time above normal values; nornal CBC; No cardiac disorder; the ferritin level more than 1000; transfusion more than 10 times.
- •Exclusion criteria: severe heart failure; patients who can not tolerate MRI; keeping liver transaminase more than five folds; repeated cytopenia; nausea and vomiting; skin rashes; and elevated serum creatinine.
排除标准
- 未提供
研究者
相似试验
招募中
不适用
Efficay comparison two oral chelators combination in patients with beta-thalassemiaIRCT20160310026998N7Tabriz University of Medical Sciences54
已完成
3 期
Compare the efficacy of combination therapy of Deferasirox and Deferiprone in reducing iron load in patients with transfusion-Dependent ß-Thalassemia.transfusion-Dependent ß-Thalassemia.Beta thalassemiaIRCT20190106042262N1Esfahan University of Medical Sciences108
已完成
不适用
?Exir research project of desferoxamin with brand name of Deferoxirthalassemia major.Cooley anaemia Severe beta thalassaemia Thalassaemia: intermedia majorIRCT2015012620818N1exir pharmacutical company100
进行中（未招募）
不适用
Phase I study to examine the effect of deferasirox on renal hemodynamics in β-thalassemia patients with transfusional iron overload - NDMedDRA version: 6.1Level: HLGTClassification code 10022958thalassemiaEUCTR2006-006838-17-ITOVARTIS FARMA8
尚未招募
4 期
Bioequivalence Study of 500 mg Deferasirox Dispersible Tablets in Healthy Thai under Fasting ConditioBioequivalence studyTCTR20170222005Research and Development36